GLP-1 receptor agonists
2 trials- 2019REWINDPrimary CV preventionIn 9,901 patients with T2DM mostly without established CV disease, dulaglutide 1.5 mg weekly reduced CV death, non-fatal MI or non-fatal stroke compared with placebo.
- 2016SUSTAIN-6CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.